What Do the Guidelines Say for Metastatic Prostate Cancer Starting Androgen Deprivation Therapy?: National Comprehensive Cancer Network, European Society for Medical Oncology, and European Association of Urology recommendations

Evan Y Yu; Silke Gillessen; Nicolas Mottet

doi:10.1016/j.euf.2018.09.015

What Do the Guidelines Say for Metastatic Prostate Cancer Starting Androgen Deprivation Therapy? National Comprehensive Cancer Network, European Society for Medical Oncology, and European Association of Urology recommendations

Evan Y Yu
, Silke Gillessen
, Nicolas Mottet

Division of Cancer Sciences (L5)

Jean Monnet University
University of Washington
Fred Hutchinson Cancer Research Center

Research output: Contribution to journal › Review article › peer-review

Abstract

Clinical trial data forms the foundation of how we treat men with metastatic prostate cancer who are initiating therapy. However, clinical trial data does not answer everything; hence, good clinical practice, pragmatism, and occasionally extrapolation drives how we manage these patients. Fortunately, multiple international guideline committees meet regularly and offer clinical guidance. In this mini-review, we focus on the United States National Comprehensive Cancer Network, European Society for Medical Oncology, and European Association of Urology (EAU) recommendations for the initial treatment of metastatic prostate cancer.

Original language	English
Journal	European Urology Focus
Early online date	1 Oct 2018
DOIs	https://doi.org/10.1016/j.euf.2018.09.015
Publication status	Published - 2018

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Research Highlights, Institutes and Platforms

Manchester Cancer Research Centre

Access to Document

10.1016/j.euf.2018.09.015

Fingerprint

Dive into the research topics of 'What Do the Guidelines Say for Metastatic Prostate Cancer Starting Androgen Deprivation Therapy? National Comprehensive Cancer Network, European Society for Medical Oncology, and European Association of Urology recommendations'. Together they form a unique fingerprint.

Cite this

@article{dc5fa5b950874a7abb30fbb8533e2b1e,

title = "What Do the Guidelines Say for Metastatic Prostate Cancer Starting Androgen Deprivation Therapy?: National Comprehensive Cancer Network, European Society for Medical Oncology, and European Association of Urology recommendations",

abstract = "Clinical trial data forms the foundation of how we treat men with metastatic prostate cancer who are initiating therapy. However, clinical trial data does not answer everything; hence, good clinical practice, pragmatism, and occasionally extrapolation drives how we manage these patients. Fortunately, multiple international guideline committees meet regularly and offer clinical guidance. In this mini-review, we focus on the United States National Comprehensive Cancer Network, European Society for Medical Oncology, and European Association of Urology (EAU) recommendations for the initial treatment of metastatic prostate cancer.",

author = "Yu, \{Evan Y\} and Silke Gillessen and Nicolas Mottet",

note = "Copyright {\textcopyright} 2018. Published by Elsevier B.V.",

year = "2018",

doi = "10.1016/j.euf.2018.09.015",

language = "English",

journal = "European Urology Focus",

issn = "2405-4569",

publisher = "Elsevier BV",

}

What Do the Guidelines Say for Metastatic Prostate Cancer Starting Androgen Deprivation Therapy? National Comprehensive Cancer Network, European Society for Medical Oncology, and European Association of Urology recommendations. / Yu, Evan Y; Gillessen, Silke; Mottet, Nicolas.
In: European Urology Focus, 2018.

Research output: Contribution to journal › Review article › peer-review

TY - JOUR

T1 - What Do the Guidelines Say for Metastatic Prostate Cancer Starting Androgen Deprivation Therapy?

T2 - National Comprehensive Cancer Network, European Society for Medical Oncology, and European Association of Urology recommendations

AU - Yu, Evan Y

AU - Gillessen, Silke

AU - Mottet, Nicolas

PY - 2018

Y1 - 2018

N2 - Clinical trial data forms the foundation of how we treat men with metastatic prostate cancer who are initiating therapy. However, clinical trial data does not answer everything; hence, good clinical practice, pragmatism, and occasionally extrapolation drives how we manage these patients. Fortunately, multiple international guideline committees meet regularly and offer clinical guidance. In this mini-review, we focus on the United States National Comprehensive Cancer Network, European Society for Medical Oncology, and European Association of Urology (EAU) recommendations for the initial treatment of metastatic prostate cancer.

AB - Clinical trial data forms the foundation of how we treat men with metastatic prostate cancer who are initiating therapy. However, clinical trial data does not answer everything; hence, good clinical practice, pragmatism, and occasionally extrapolation drives how we manage these patients. Fortunately, multiple international guideline committees meet regularly and offer clinical guidance. In this mini-review, we focus on the United States National Comprehensive Cancer Network, European Society for Medical Oncology, and European Association of Urology (EAU) recommendations for the initial treatment of metastatic prostate cancer.

U2 - 10.1016/j.euf.2018.09.015

DO - 10.1016/j.euf.2018.09.015

M3 - Review article

C2 - 30287277

SN - 2405-4569

JO - European Urology Focus

JF - European Urology Focus

ER -